NAD injection side effects fall into two groups. Some are general injection-site reactions seen with injected medications, such as stinging, redness, soreness or bruising, which have not been measured specifically for NAD+. Others affect the whole body, such as flushing, nausea and chest pressure, mostly described in IV research. The main human data for NAD+ shots comes from one small 2026 preprint (openRxiv preprint, 2026). Compounded NAD+ is not FDA-approved.
Key takeaways
- Two kinds of side effects come up with NAD+ injections, general injection-site reactions and body-wide reactions such as flushing and nausea, but no study gives a reliable rate for either.
- The main human safety data for NAD+ given under the skin or into muscle comes from one small, industry-funded 2026 preprint, with NAD+ groups of 6 and 4 people.
- IV NAD+ has more data, which shows stomach symptoms, raised heart rate and chest pressure during infusions that stopped when the infusion ended.
- NAD+ injections have no FDA label, so there is no official list of who should avoid them, and eligibility is a clinical decision.
- Signs of an allergic reaction, chest pain, trouble breathing or fainting mean calling 911, not sending a message.
What are NAD injection side effects?
NAD+ injection side effects are either local, at the injection site, or body-wide, such as flushing and nausea. Most of what is known comes from IV research and clinical experience rather than controlled trials of injections.
NAD+ (nicotinamide adenine dinucleotide) is a molecule cells use to run energy chemistry. Injection pathways give it subcutaneously (into the fatty layer under the skin) or intramuscularly (into a muscle).
General injection-site reactions that can occur with injected medications (not measured specifically for NAD+):
- stinging or burning as the medication goes in
- redness or warmth
- soreness or tenderness
- a small lump under the skin
- bruising
The main injection-route NAD+ data, a 2026 preprint, reported some discomfort across routes without breaking it down into specific reactions or rates (openRxiv preprint, 2026).
Body-wide reactions reported with IV NAD+ or with related compounds such as NR:
- flushing or a feeling of warmth
- nausea or stomach upset
- headache
- tiredness
- lightheadedness
- chest pressure or tightness
The best-documented list comes from IV research. A 2026 narrative review of human IV NAD+ studies lists nausea, cramping, flushing and chest discomfort as the reported adverse effects (Frontiers in Aging review, 2026). A 2024 pilot summarized earlier clinician and participant reports of nausea, diarrhea, muscle cramping, chest pains and dizziness with NAD+ IV (openRxiv preprint, 2024). Headache and tiredness appear in the side effect list for oral NR, a related compound, rather than in NAD+ studies (ClinicalTrials.gov, NCT03482167).
What is missing matters just as much. No published study gives a reliable percentage for how often these reactions happen with subcutaneous NAD+, or how long they last. In IV research, symptoms resolved once the infusion was completed (Frontiers in Aging retrospective, 2026). If a page promises that injection symptoms fade within a set number of hours, it is not citing data that exists.
What the research actually measured, and its limits
The human research on NAD+ side effects is small and short, and part of it is industry-funded. Almost all of it studies IV infusions, not injections. Several studies compare NAD+ with NR (nicotinamide riboside), a precursor the body can convert into NAD+.
| Study and design | Route and size | What it found | Main limitation |
|---|---|---|---|
| 2019 infusion pilot (Front Aging Neurosci, 2019) | IV, one 6-hour infusion, small group | Plasma NAD+ and its breakdown products did not change for the first 2 hours. NAD+ was rapidly cleared from plasma | Built to track how NAD+ moves through the body, not to measure side effects |
| 2024 randomized, placebo-controlled pilot (openRxiv preprint, 2024) | Single dose of IV NAD+, IV NR, oral NR or IV saline | NAD+ IV was associated with more, and more severe, adverse experiences than NR IV. Mean tolerable infusion time for NR IV was 75% shorter than for NAD+ IV. White blood cells and neutrophils rose after NAD+ IV. No attributable adverse events over 14 days | Preprint, not peer-reviewed. Authors affiliated with the maker of the NR product being tested |
| 2026 retrospective records review (Frontiers in Aging retrospective, 2026) | IV on four consecutive days, 30-day follow-up | Moderate to severe stomach symptoms, raised heart rate and chest pressure during NAD+ infusions. Infusions averaged 97 minutes vs 37 for NR. No significant change in the liver enzymes ALT and AST or in kidney, inflammation or thyroid markers | Not randomized. Records come from clients in a commercial setting |
| 2026 injection-route trials (openRxiv preprint, 2026) | NAD+ groups: subcutaneous 6, intramuscular 4, IV 5, within a 45-person randomized trial | Some discomfort across routes. No attributable unexpected adverse events and no concerning safety signals | Preprint. Very small groups. Funded by an NR manufacturer whose employees are authors |
| 2026 narrative review (Frontiers in Aging review, 2026) | Human IV NAD+ and precursor studies, 2018 to 2026 | Evidence is sparse and long-term safety data are lacking. Not enough to support routine IV use | Summarizes small, mostly uncontrolled studies |
The 2026 records review found two more things. HDL cholesterol fell significantly in the NAD+ IV group (Frontiers in Aging retrospective, 2026). Alkaline phosphatase, a liver and bone enzyme, also fell but stayed within normal ranges. The injection-trial authors recommend checking metabolic and inflammatory blood panels in future studies and in clinical settings (openRxiv preprint, 2026).
Oral NR shows what better evidence looks like. A 12-week double-blind, randomized, placebo-controlled pilot randomized 52 older adults with mild cognitive impairment, and 42 completed it. It reported no serious adverse effects, and side effects were comparable to placebo (Alzheimer's & Dementia, 2025). Injectable NAD+ has nothing comparable.
One popular claim also needs context. Many pages say NAD+ falls steadily with age, but the 2026 review notes that recent large-scale human data indicate whole-blood NAD+ does not decline with healthy aging per se (Frontiers in Aging review, 2026). The NAD+ evidence summary goes deeper on the research.
Why do NAD+ injections cause flushing or nausea?
Nobody has proven why. The likely explanations come from IV research and lab biology, and none has been confirmed for subcutaneous NAD+.
- Breakdown products. NAD+ cannot enter cells intact. Most infused NAD+ is broken down outside cells into NMN, then NR, and some of it further into nicotinamide and nicotinic acid (openRxiv preprint, 2024). The 2019 infusion pilot found a breakdown pattern consistent with this (Front Aging Neurosci, 2019). Nicotinic acid is niacin, which is widely known to cause flushing. The link is plausible but not proven.
- Adenosine. Adenosine is a signaling molecule that affects blood vessels and heart rhythm. The 2026 review calls adenosine formation after IV NAD+ plausible, but says it is uncertain how much happens in humans (Frontiers in Aging review, 2026).
- An inflammatory "danger signal". NAD+ outside cells is considered a danger signal during cell damage and can have proinflammatory effects (Frontiers in Aging retrospective, 2026). One pilot saw white blood cells and neutrophils rise after NAD+ IV, which the authors suggest indicates an inflammatory response (openRxiv preprint, 2024).
Related compounds show a similar pattern. A trial consent document for oral NR lists possible headache, warmth, hot flushing, stomach discomfort and fatigue (ClinicalTrials.gov, NCT03482167).
In IV studies, symptoms lengthened NAD+ infusions, which suggests they are linked to how fast NAD+ goes in (Frontiers in Aging retrospective, 2026). Whether that applies to injections is unknown.
Are NAD+ injections safer than IV NAD+?
No study has compared NAD+ injections with IV NAD+ head to head. "Gentler" is plausible, but it has not been shown.
IV NAD+ has the most tolerability data. That data shows symptoms during the infusion that limit how fast NAD+ can be given and that stop when the infusion ends (Frontiers in Aging retrospective, 2026). For injections, there is one small preprint group per route. It found discomfort but no concerning safety signals (openRxiv preprint, 2026). Groups of six and four people cannot show that one route is safer than another.
The common argument is that shots deliver NAD+ more slowly, so they cause fewer body-wide effects. That explanation is reasonable, but it is unproven. Injections also avoid IV-specific issues such as long chair time and problems at the cannula site, the thin tube placed in a vein. In exchange, they bring their own injection-site reactions.
For absorption, convenience and time, see NAD+ injections vs IV therapy. A NAD+ nasal spray is another route. No comparative safety data exists for it either, and NAD+ nasal spray vs injection covers how the routes differ.
Who should avoid NAD+ injections?
No FDA-approved NAD+ injection exists, so there is no official contraindication list. That is a reason to be more careful, not less.
A licensed clinician will ask about:
- pregnancy or breastfeeding, because the available research offers no safety data
- active or past cancer, because a trial consent document noted a few animal reports linking NAD+-boosting compounds to cancer growth in animals that already had cancer (ClinicalTrials.gov, NCT03482167). This is an animal signal only, but your clinician should know about any cancer history
- known allergies to any ingredient
- heart symptoms or heart conditions, given the chest pressure and raised heart rate seen with IV NAD+
- current medications and supplements, including other NAD+ precursors
NAD+ through New Blue is for adults 21 and older. Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.
When to message a clinician and when to get emergency care
Message your clinician about reactions that linger, spread or keep coming back. Call 911 for anything that affects breathing, the heart or consciousness.
Message your clinician if you notice:
- redness, warmth or swelling at the injection site that spreads or doesn't settle
- pus, worsening pain or fever, which can be signs of infection
- nausea, headache or flushing that comes back with every dose
- anything new that worries you
Call 911 for:
- hives with swelling of the face, lips or throat
- trouble breathing
- chest pain
- fainting
- a racing heartbeat that doesn't settle
New Blue is not for emergencies.
When you contact a clinician, tell them when symptoms started relative to the dose and how long they lasted. List your medications and supplements, and mention any recent change in product or pharmacy. For questions about giving the medication, follow your clinician's guidance and pharmacy instructions.
What is the FDA status of compounded NAD+?
Compounded NAD+ is not FDA-approved. Compounded medications are not FDA-approved, and there is no FDA-approved NAD+ injection.
Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Compounding means a licensed pharmacy or outsourcing facility prepares a medication. That is different from a manufacturer producing an FDA-approved product, and it is why compounded NAD+ is not FDA-approved. Without an approved product, there is also no official label that sets out side effect rates or who should avoid the medication.
The source of the product matters. Research-chemical vials sold online skip both the prescriber and the licensed pharmacy, so no one screens you and no pharmacy stands behind the product. The compounding disclosure explains how compounded products reach patients through licensed channels.
How access works through New Blue
New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.
- You complete an asynchronous structured intake covering your health history, medications and goals.
- A licensed clinician reviews it. Some treatments or states may require a live visit. Consultation timing varies by clinician availability.
- If appropriate, the clinician may prescribe NAD+ injections.
- If prescribed, a licensed partner pharmacy ships the medication directly to you.
Availability varies by state. Check state availability before you start. For current pricing, see the NAD+ injectable treatment page. If treatment isn't appropriate, refunds follow our refund policy. New Blue is LegitScript certified.
Frequently Asked Questions
Are NAD+ injection side effects dangerous?
Small studies reported discomfort with injections and, with IV NAD+, moderate to severe stomach symptoms, raised heart rate and chest pressure that stopped when the infusion ended. Long-term safety data are lacking, so the full risk is unknown. Signs of an allergic reaction, chest pain, trouble breathing or fainting need emergency care right away.
How long do NAD+ injection side effects last?
No published study gives a duration for side effects from subcutaneous or intramuscular NAD+. In IV studies, symptoms resolved when the infusion was completed. Tell your clinician about any reaction that lingers, spreads or returns with each dose.
Do NAD+ injections cause flushing like niacin?
It is plausible, but it has not been proven. Infused NAD+ is broken down outside cells, and some of it becomes nicotinic acid, which is niacin. No study has confirmed that this explains flushing after NAD+ injections.
Is NAD+ nasal spray easier to tolerate than injections?
No study has compared the safety of NAD+ nasal spray with NAD+ injections. The two routes deliver NAD+ differently, and neither has large human trials. A licensed clinician can discuss which format, if any, fits your situation.
Is NAD+ safe long term?
Nobody knows. A 2026 narrative review concluded that long-term safety data for IV NAD+ are lacking and that larger randomized trials are needed. Data for injections are even more limited.
What is the FDA status of compounded NAD+?
Compounded NAD+ is not FDA-approved, and no FDA-approved NAD+ injection exists. Compounded medications are not FDA-approved as a category. Compounded NAD+ is prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities.
Sources
- Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 2026. https://pubmed.ncbi.nlm.nih.gov/41704678/
- Randomized, placebo-controlled, pilot clinical study evaluating acute NiagenĀ®+ IV and NAD+ IV in healthy adults. openRxiv (preprint), 2024. https://doi.org/10.1101/2024.06.06.24308565
- Preliminary Safety Analysis of Two Pilot Clinical Trials Involving Injections of NiagenĀ®, Nicotinamide Riboside Chloride. openRxiv (preprint), 2026. https://doi.org/10.64898/2026.04.28.26352007
- Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Frontiers in Aging, 2026. https://doi.org/10.3389/fragi.2026.1887175
- A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience, 2019. https://doi.org/10.3389/fnagi.2019.00257
- NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment. ClinicalTrials.gov, undated. https://clinicaltrials.gov/study/NCT03482167
- A phase-II randomized controlled pilot and feasibility study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Alzheimer's & Dementia, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12724761/
Medical disclaimer: This article is for education only and is not medical advice. Treatment decisions are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider.
Related treatment guide
Related reading
Content review & editorial standards
This page is educational content from the New Blue Health Editorial Team. It is checked under the New Blue Health Content Review Policy and Editorial Policy and should not replace individualized medical advice from a licensed clinician. For how we evaluate evidence, see Evidence Methodology and Clinical Sources & References.